(Q31157033)

29 June 2017

1 reference

title

Gut peptides and type 2 diabetes mellitus treatment (English)

1 reference

29 June 2017

0 references

1

Bo Ahrén

1 reference

29 June 2017

1 October 2003

1 reference

29 June 2017

Current diabetes report

1 reference

29 June 2017

3

1 reference

29 June 2017

5

1 reference

29 June 2017

365-372

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-003-0079-9

29 June 2017

0 references

cites work

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

1 reference

12 December 2020

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

1 reference

12 December 2020

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

1 reference

12 December 2020

Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat

1 reference

12 December 2020

Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line

1 reference

12 December 2020

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

1 reference

12 December 2020

Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans

1 reference

12 December 2020

Cholecystokinin and the regulation of insulin secretion

1 reference

12 December 2020

The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes

1 reference

12 December 2020

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

1 reference

12 December 2020

The pathogenesis of NIDDM involves a defective expression of the GIP receptor

1 reference

12 December 2020

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

12 December 2020

Incretin hormones--an update.

1 reference

12 December 2020

A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes

1 reference

12 December 2020

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions

1 reference

12 December 2020

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

1 reference

12 December 2020

Amplification of exocytosis by Ca2+-induced Ca2+ release in INS-1 pancreatic beta cells

1 reference

12 December 2020

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

12 December 2020

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

12 December 2020

A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.

1 reference

12 December 2020

Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells

1 reference

12 December 2020

Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide

1 reference

12 December 2020

The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function

1 reference

12 December 2020

Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes

1 reference

12 December 2020

Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes

1 reference

12 December 2020

Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations

1 reference

12 December 2020

Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.

1 reference

12 December 2020

Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.

1 reference

12 December 2020

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

12 December 2020

Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance.

1 reference

12 December 2020

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

1 reference

12 December 2020

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state

1 reference

12 December 2020

1,5-Anhydro-d-fructose increases glucose tolerance by increasing glucagon-like peptide-1 and insulin in mice

1 reference

12 December 2020

Gastric inhibitory polypeptide: the neglected incretin revisited

1 reference

12 December 2020

Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice

1 reference

12 December 2020

Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.

1 reference

12 December 2020

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes

1 reference

12 December 2020

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

12 December 2020

The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients

1 reference

12 December 2020

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39

1 reference

12 December 2020

Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women

1 reference

12 December 2020

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

12 December 2020

Biological actions and therapeutic potential of the glucagon-like peptides

1 reference

12 December 2020

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

12 December 2020

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

1 reference

12 December 2020

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

12 December 2020

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

1 reference

12 December 2020

Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.

1 reference

12 December 2020

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

1 reference

12 December 2020

10.1007/S11892-003-0079-9

Identifiers

DOI

1 reference

PubMed ID

12975025

Dimensions Publication ID

29 June 2017

0 references

1 reference

PubMed ID

12975025